Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. (September 2022)

• Record Type: Journal Article
• Authors: McAllister, Peter; Kudrow, David; Cady, Roger; Hirman, Joe; Ettrup, Anders
• Is Part Of: Cephalalgia. Volume 42:Number 10(2022)
• Page Start: 1005
• Page End: 1012
• Publication Date: 2022-09
• Subjects: Eptinezumab -- chronic migraine -- migraine burden; Headache -- Periodicals; 616.8491
• DOI: 10.1177/03331024221089567
• Languages: English
• ISSNs: 0333-1024

Abstract

Abstract: Objective: To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine following eptinezumab treatment. Methods: PROMISE-2 was a double-blind, placebo-controlled, parallel-group trial that randomized adults with chronic migraine to eptinezumab 100 mg, 300 mg, or placebo IV every 12 weeks for up to 24 weeks (2 infusions). Headache episodes (migraine and non-migraine) and their characteristics were reported in daily electronic diaries during the 28-day baseline and throughout the 24-week treatment period. Results: A total of 1072 patients were included in this post hoc analysis. Mean monthly headache days decreased by 8.9 (100 mg) and 9.7 (300 mg) compared to a 7.3 decrease in placebo over the first 4-week interval post initial dose and reductions were maintained throughout the 24-week treatment period. Mean monthly headache episodes also decreased by 8.4 (100 mg) and 9.0 (300 mg) compared to a decrease of 7.1 with placebo. The proportion of headache episodes that were migraine attacks decreased by 11.2% (100 mg), 12.4% (300 mg), and 3.9% (placebo), and among remaining headaches decreases in severe pain, nausea, phonophobia, photophobia, and physical activity limitations were numerically greater than placebo. Conclusions: Patients with chronic migraine treated with eptinezumab decreased the monthly severity and frequency of headache days and episodes more than placebo. Beyond decreased headache frequency, patients treated with eptinezumab reported a reduction in the percent of remaining headache episodes that were migraine attacks, as well as a decrease in burdensome symptoms of headache episodes, indicating additional decreased headache severity after eptinezumab treatment. Trial registration: ClinicalTrials.gov Identifier: NCT02974153; registered November 23, 2016.